Foundayo vs Saxenda

Foundayo (orforglipron) and Saxenda (liraglutide 3 mg) are both FDA-approved for the same purpose: chronic weight management in adults with obesity or overweight plus a weight-related comorbidity. This is a genuine head-to-head comparison between two drugs competing for the same prescriptions, not a cross-indication contrast. The most consequential differences are form of delivery, magnitude of weight loss in trials, and approval history.

Same Indication, Real Clinical Choice

Foundayo received FDA approval on April 1, 2026 for chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity, as an adjunct to reduced-calorie diet and increased physical activity. Saxenda has carried the same class of obesity indication since December 2014, and in December 2020 its label was expanded to include adolescents aged 12 to 17 with body weight over 60 kg. Both drugs are approved under the obesity management indication — the clinical question is which is the better fit for a given adult patient.

Route Is the Headline Differentiator

Saxenda is a once-daily subcutaneous injection titrated over five weeks through six pre-filled pens: 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, and 3.0 mg. Patients self-inject into the abdomen, thigh, or upper arm. The 6-pen titration pack and pen disposal logistics add a practical burden that some patients find manageable and others find prohibitive.

Foundayo is a once-daily oral tablet taken with or without food, at any time, with any beverage. No fasting window is required, unlike Rybelsus (the other oral GLP-1, approved only for type 2 diabetes) which requires a strict 30-minute empty-stomach protocol. Foundayo is the first GLP-1 receptor agonist offering this level of oral flexibility for chronic weight management, and for patients with needle aversion or injection fatigue it changes the calculus entirely.

Weight Loss From Pivotal Trials

In ATTAIN-1 (72 weeks), adults on Foundayo 36 mg daily lost approximately 12.4% of baseline body weight versus about 0.9% on placebo. In the SCALE Obesity and Prediabetes trial (56 weeks), adults on Saxenda 3 mg daily lost approximately 8.0% of baseline body weight versus about 2.6% on placebo.

These trials ran for different durations in different populations, so cross-trial comparison requires caution. The directional message is consistent: Foundayo produced greater mean weight reduction in ATTAIN-1 than Saxenda produced in SCALE. The gap — roughly 4 percentage points at mean — is clinically meaningful. For patients prioritizing maximum weight loss, tirzepatide (Zepbound, approximately 22.5% in SURMOUNT-1) and semaglutide (Wegovy, approximately 16.9% in STEP 1) outperform both agents in their respective trials.

Side Effect Profile

Both drugs activate the GLP-1 receptor and share the class side-effect pattern: nausea, vomiting, diarrhea, constipation, dyspepsia, and abdominal discomfort. Saxenda's SCALE trial rates were among the highest observed in the obesity drug class at the time: nausea 39%, diarrhea 21%, vomiting 16%, constipation 19%. Foundayo's ATTAIN-1 GI rates were generally lower: nausea 21 to 27%, diarrhea 15 to 20%, vomiting 10 to 16%, constipation 8 to 14%.

Both drugs carry the thyroid C-cell tumor boxed warning, are contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2, and share pancreatitis and gallbladder event risks. Saxenda has injection-site reactions that do not apply to an oral tablet. Slow dose titration reduces GI burden on either agent.

Approval History and Pediatric Use

Saxenda launched in early 2015, giving it over a decade on the U.S. market. Its pediatric expansion in 2020 reflects a specific adolescent obesity trial (the SCALE Teens study). Foundayo launched in April 2026 and has adult data only; no pediatric approval or clinical trial in patients under 18 has been reported.

For adult patients without a history on either agent, both are viable starting points. For adolescent patients or families, Saxenda is the only option of the two with an FDA-approved label covering that age group.

Coverage and Cost Considerations

Saxenda's twelve-year formulary history means some commercial plans have established prior-authorization pathways for it. Plans using step therapy sometimes require an older obesity drug before approving a newer one, which can work in Saxenda's favor. Foundayo's coverage is still being established across commercial insurers as of its April 2026 launch; Eli Lilly is bridging gaps with savings card programs for eligible commercially-insured patients. Neither drug is currently covered by Medicare Part D for weight loss alone under federal law. Patients should confirm formulary status with their specific plan before filling.

This page is for informational purposes only and does not constitute medical advice. Prescribing decisions should involve a patient and their healthcare provider, guided by the most current FDA labeling, individual medical history, and insurance coverage.